글로벌 콜로니 자극 인자 시장 – 2030년까지의 산업 동향 및 예측

군집 자극 인자 시장 분석 및 규모

집락 자극 인자(Colony Stimulating Factors)는 감염과 싸우는 면역 세포의 생성을 촉진하는 호르몬과 유사한 단백질입니다. 집락 자극 인자는 우리 몸의 다양한 세포에서 생성되며 몸 전체를 여행하면서 특수한 집락 자극 인자 수용체가 있는 세포에 결합할 수 있습니다. 집락 자극 인자는 면역 세포의 합성을 자극할 수 있기 때문에 백혈구 형성을 촉진하는 약물로 사용됩니다. 화학 요법이나 특정 면역 결핍 질환으로 면역 체계가 파괴된 사람들에게는 생명을 구하는 치료법이 될 수 있습니다. 집락 자극 인자는 또한 혈액 줄기 세포 이식에 사용되는 중요한 약물입니다.                               

Data Bridge Market Research는 2022년에 77억 2천만 달러였던 콜로니 자극 인자 시장이 2030년까지 174억 2천만 달러로 급증할 것으로 분석했으며, 예측 기간 동안 10.70%의 CAGR을 기록할 것으로 예상합니다. "골수 이식"은 다양한 만성 질환에 대한 골수 이식의 빈번한 필요성으로 인해 콜로니 자극 인자 시장의 적용 부문을 지배합니다.

Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

감염에 대한 반응으로, 집락 자극 인자는 백혈구(대부분 호중구와 같은 과립구)의 발달을 촉진하는 당단백질입니다. 외인성 집락 자극 물질은 골수의 줄기 세포가 특정 유형의 백혈구를 더 많이 생성하도록 촉진합니다. 새로운 백혈구는 혈류로 들어가 질병과 싸우기 시작합니다. 백혈구 수치가 낮아지고(호중구 감소증) 감염 위험이 있는 암 치료를 받는 환자에게는 집락 자극제가 투여됩니다. 집락 자극 물질을 투여받는 환자는 호중구 감소증에 걸리는 시간이 줄어듭니다.            

글로벌 콜로니 자극 인자 시장 역학

운전자

• 혈액학적 질환의 유병률 증가

The prevalence of hematological disorders, such as leukemia and anemia, has been on the rise globally. Colony Stimulating Factors are used in the treatment of these conditions to stimulate the production of blood cells. The increasing incidence of such disorders is a significant driver for the colony stimulating factors market.

• Growing aging population

As the global population continues to age, there is an increased demand for therapies that can address age-related conditions, including those related to the hematopoietic system. This demographic shift has contributed to the growth of the colony stimulating factors market, as elderly individuals are more prone to hematological disorders.

• Advancements in biotechnology and healthcare 

Advances in biotechnology, including the development of biosimilars, have played a pivotal role in the colony stimulating factors market's expansion. Biosimilars offer more cost-effective options for colony stimulating factors therapy, making them more accessible to a broader patient base.

• Growing investment for healthcare facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expansion of emerging markets

Emerging markets, especially in Asia and Latin America, have shown a growing demand for healthcare services. The increasing awareness of colony stimulating factors and their potential in treating hematological disorders in these regions presents a significant growth opportunity for global Colony Stimulating Factors manufacturers.

• Development of Novel Colony Stimulating Factors Therapies

Research and development in the field of biotechnology and immunology can lead to the development of novel colony stimulating factors therapies. Innovations such as longer-acting colony stimulating factors, personalized medicine approaches, or new delivery methods can open up new avenues in the market and improve patient outcomes.

Restraints

• High treatment costs

Colony stimulating factors therapies can be expensive, which may limit access to these treatments for some patients, especially in regions with limited healthcare resources. The high cost of colony stimulating factors can be a significant restraint on market growth.

• Stringent regulatory requirements

Stringent regulatory requirements for the approval of new colony stimulating factors products can be a restraint. Companies face hurdles in navigating complex and evolving regulatory pathways, leading to delays in product launches and increased development costs.

Challenges

• Potential adverse effects

Colony stimulating factors therapy can have side effects, including bone pain, fever, and allergic reactions. These adverse effects can limit the use of colony stimulating factors in certain patient populations, and concerns about safety and tolerability can be a challenge for market expansion.

• Limited awareness and access

In some regions, there may be limited awareness about colony stimulating factors therapies, leading to underdiagnosis and undertreatment of hematological disorders. Additionally, unequal access to healthcare resources can hinder patient access to colony stimulating factors treatments, creating challenges for market growth.

This colony stimulating factors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the colony stimulating factors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In March 2023, Coherus BioSciences received U.S. FDA approval for its pegfilgrastim-cbqv (Udencya), a pegfilgrastim biosimilar for managing febrile neutropenia induced by chemotherapy.
• In September 2022, Spectrum Pharmaceuticals, Inc. received U.S. FDA approval for its ROLVEDON (eflapegrastim-xnst) injection, which is intended to decrease the incidence of infection, as manifested by febrile neutropenia in adult patients with non-myeloid-malignancies-receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Global Colony stimulating factors Market Scope

The colony stimulating factors market is segmented on the basis of type, drug, application, dosage, route of administration, end-users and distribution channel analysis. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Macrophage–Colony-Stimulating Factor (M-CSF)
• Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3)
• Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
• Granulocyte–Colony-Stimulating Factor (G-CSF)

Drug

• Pegfilgrastim
• Tbo-filgrastim
• Sargramostim
• Filgrastim

Application

• Aplastic Anemia
• Bone Marrow Transplantation
• Neutropenia
• Neutropenia Associated with Chemotherapy
• Neutropenia Associated with Radiation
• Peripheral Progenitor Cell Transplantation

Dosage

• Injection
• Tablets
• Capsule
• Others

Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Colony stimulating factors Market Regional Analysis/Insights

The colony stimulating factors market is analysed and market size insights and trends are provided by country, type, drug, application, dosage, route of administration, end-users and distribution channel analysis as referenced above.

The countries covered in the colony stimulating factors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the colony stimulating factors market because of the rising prevalence of cancer in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate.

Asia-Pacific region is expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The colony stimulating factors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for colony stimulating factors market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the colony stimulating factors market. The data is available for historic period 2010-2020.

Competitive Landscape and Colony stimulating factors Market Share Analysis

군집 자극 인자 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 군집 자극 인자 시장과 관련된 회사의 초점에만 관련이 있습니다.

군집 자극 인자 시장에서 활동하는 주요 업체는 다음과 같습니다.

• Intas Pharmaceuticals Ltd. (인도)
• 사노피(프랑스)
• 노바티스 AG(스위스)
• Teva Pharmaceutical Industries Ltd. (아일랜드)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• Biocon(인도)
• Dr. Reddy's Laboratories Ltd. (인도)
• 암젠 주식회사(미국)
• 머크 KGaA(독일)
• 다케다제약 주식회사(일본)
• Thermo Fisher Scientific Inc. (미국)
• STADA Arzneimittel AG(독일)
• Emcure Pharmaceuticals Limited. (인도)
• 셀트리온 주식회사(한국)
• BIOCAD(러시아)
• Coherus BioSciences(미국) 
• 존슨앤존슨 프라이빗 리미티드(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• 애벗(미국)

SKU-68380